Skip to main content
TipRanks
Go Ultimate75% OFF

Kura Oncology (KURA) AI Stock Analysis

972 Followers
KURA

Kura Oncology

(NASDAQ:KURA)

Select Model
Rating:46Neutral
Price Target:$7.50â–¼(-3.47% Downside)
Action:reiterated
Date:11/11/26

The score is held down primarily by weak financial performance (large ongoing losses, equity erosion and renewed cash burn) and bearish technicals (downtrend and negative momentum). A notably positive earnings call—highlighting strong commercial execution, pipeline progress, and improved funding visibility—partially offsets these risks, while valuation provides limited support due to negative earnings and no dividend.

Positive Factors
Commercial adoptionRapid growth in product revenue, patient starts, and prescriptions indicates strengthening commercial adoption rather than reliance on a single initial launch wave. Expanding utilization can build a larger treated base, improve recurring refill potential, and support a more durable oncology franchise.
Negative Factors
Persistent lossesLarge operating and net losses show that revenue growth has not yet translated into economic breakeven. Continued investment in commercialization and clinical development may require substantial external funding, while the cost structure could remain a durable constraint on future earnings and cash generation.

Kura Oncology (KURA) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%KURA-29.87%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$713.90M
Dividend Yield
―
Average Volume (3M)
2.14M
Price to Earnings (P/E)
-2.4
Beta (1Y)
1.55
Revenue Growth
-23.76%
EPS Growth
-33.09%
Country
US
Employees
260
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Kura Oncology Business Overview & Revenue Model

Company Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; D...

Kura Oncology Earnings Call Summary

Earnings Call Date:Nov 10, 2026(Q3-2026)|% Change Since:2.64%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was strongly positive, driven by 53% sequential COMZIFTI revenue growth, 30% growth in new patient starts, expanding prescribing accounts, majority market share, substantial ASH data visibility, progress toward frontline registration, FDA alignment for a darlafarnib registrational study, and a strengthened funding position. The principal negatives were lower collaboration revenue, immature duration data, ongoing competition, and the fact that just under half of the incident NPM1 population is receiving menin inhibitor therapy. Management presented these items as manageable opportunities or execution priorities rather than material setbacks.

Positive Updates

Strong COMZIFTI Commercial Growth
Third-quarter COMZIFTI net product revenue reached $13.9 million, up 53% sequentially, while new patient starts increased approximately 30% to about 150. Total prescriptions exceeded 2.4 thousand, up 65%.

Negative Updates

Decline in Collaboration Revenue
Third-quarter collaboration revenue from the Kyowa Kirin partnership was $8.9 million, down from $20.8 million in the prior-year quarter. Kura updated current-year collaboration revenue guidance to $40 million to $45 million, while maintaining guidance of $90 million to $110 million in each of 2027 and 2028.

Company Guidance

Management expects collaboration revenue of $40 million to $45 million for 2020 and is maintaining guidance of $90 million to $110 million in each of 2027 and 2028; September 30th cash resources, subsequent financing proceeds, and approximately $180 million in anticipated Kyowa Kirin payments are expected to support the current operating plan beyond the initial Ziftomenib top line results expected in 2028. The first top line results from the intensive chemotherapy trial in KOMET-017 are expected in 2028, while Kura plans to submit an IND by the end of this year and initiate an approximately 40-patient darlafarnib monotherapy study in the first half of 27, complete RCC enrollment in the first half of 27 and report initial data in the second half, and dose the first PDAC patient in the first half of 27 with the potential for preliminary data in the second half. The company continues to guide to the approximately 6 months duration of treatment and described 5 to 6 months as steady state.

Kura Oncology Financial Statement Overview

Summary

Revenue is scaling and reported gross margins are very high, but profitability remains deeply negative (large operating and net losses). Balance-sheet risk is elevated due to sharp equity erosion and higher debt-to-equity, and cash flow has turned meaningfully negative again with volatile burn.

Income Statement

38Negative

Balance Sheet

34Negative

Cash Flow

41Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue79.31M67.48M53.88M000
Gross Profit78.08M67.42M53.88M-849.00K00
EBITDA-290.29M-275.82M-169.50M-150.23M-134.85M-129.49M
Net Income-292.87M-278.67M-173.98M-152.63M-135.84M-130.47M
Balance Sheet
Total Assets566.50M738.36M760.16M448.94M456.31M534.05M
Cash, Cash Equivalents and Short-Term Investments492.10M667.24M727.39M423.96M437.99M517.96M
Total Debt25.83M20.46M16.59M17.20M14.02M6.88M
Total Liabilities548.54M564.23M346.52M51.66M36.03M27.44M
Stockholders Equity17.96M174.13M413.64M397.27M420.28M506.61M
Cash Flow
Free Cash Flow-89.12M-70.70M133.84M-124.99M-110.69M-105.70M
Operating Cash Flow-85.57M-64.06M134.32M-124.82M-110.06M-104.55M
Investing Cash Flow12.98M-13.10M-101.59M15.56M32.63M-126.83M
Financing Cash Flow35.25M1.79M154.42M94.78M38.56M-3.44M

Kura Oncology Technical Analysis

Technical Analysis SentimentNegative
Last Price7.77

Price Trends

50DMA10.17Negative
100DMA10.61Negative
200DMA9.77Negative

Market Momentum

MACD-0.79Positive
RSI37.10Neutral
STOCH24.32Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KURA, the sentiment is Negative. The current price of 7.77 is below the 20-day moving average (MA) of 8.96, below the 50-day MA of 10.17, and below the 200-day MA of 9.77, indicating a bearish trend. The MACD of -0.79 indicates Positive momentum. The RSI at 37.10 is Neutral, neither overbought nor oversold. The STOCH value of 24.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KURA.

Kura Oncology Risk Analysis

Kura Oncology disclosed 75 risk factors in its most recent earnings report. Kura Oncology reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.We are a "smaller reporting company" and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to smaller reporting companies could make our common stock less attractive to investors.Q4, 2025
2.Post-approval results for KOMZIFTI in larger numbers of patients, broader populations or real world clinical practice may not be consistent with the results from our clinical trials.Q4, 2025
3.Our ability to generate revenue is highly dependent on the successful commercialization of KOMZIFTI in the United States and continued global development of ziftomenib. If we are unable to successfully commercialize KOMZIFTI in the United States, or to expand ziftomenib's indications of use or market opportunity, our ability to generate meaningful revenue or achieve profitability will be materially and adversely affected.Q4, 2025

Kura Oncology Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

KURA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GERNGERN51Neutral$622.98M-13.79-22.27%―18.60%37.60%
CTMXCTMX47Neutral$444.73M-4.52-33.97%―-87.66%-210.45%
KURAKURA46Neutral$713.90M-2.35-336.24%―-23.76%-33.09%
ORICORIC44Neutral$814.71M-5.82-35.35%――28.64%
ZNTLZNTL44Neutral$167.05M-0.89-75.82%―-100.00%7.45%
PRLDPRLD38Underperform$275.32M-4.37-75.35%―220.34%55.73%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%400%KURAGERNCTMXZNTLORICPRLDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
KURA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
KURAKura Oncology7.77-3.08-28.39%
GERNGeron Corporation0.97-0.16-14.42%
CTMXCytomX Therapeutics Inc.2.04-1.51-42.54%
ZNTLZentalis Pharmaceuticals Inc1.700.3828.79%
ORICOric Pharmaceuticals Inc7.86-4.20-34.83%
PRLDPrelude Therapeutics, Inc.3.451.80109.09%

Kura Oncology Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Kura Oncology Establishes Caspian Partnership for Cardiometabolic Focus

Positive
Sep 9, 2026

On September 8, 2026, Caspian Therapeutics completed a $50.0 million Series A preferred stock financing, in which Kura Oncology invested $4.3 million, leaving Kura with approximately 49.2% of Caspian’s outstanding capital stock. The transaction bring...

Business Operations and StrategyExecutive/Board Changes

Kura Oncology Appoints Jennifer Fulk as New CFO

Positive
Sep 8, 2026

Effective September 8, 2026, Kura Oncology appointed industry veteran Jennifer Fulk as Chief Financial Officer, principal financial officer and principal accounting officer, replacing Troy E. Wilson and Thomas Doyle in those specific roles. Fulk brin...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026